Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Klaus-Georg Erich Werner
Associate Professor of Pediatrics
Pediatrics, Neurology
klaus.werner@duke.edu
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Duke Appointments & Affiliations
Previous Duke Appointments & Affiliations
global-scholarship {hide_children: true, active: false, enabled: false}
Global Scholarship
keywords {hide_children: true, active: false, enabled: false}
Keywords
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
scholarly-works {hide_children: true, active: false, enabled: true}
Scholarly Works
Featured Works
Journal articles
teaching-mentoring {hide_children: true, active: false, enabled: false}
Teaching & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: false}
Professional Activities
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
INTERVENTIONAL, EFFICACY, SAFETY, PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OPEN-LABEL EXT
Clinical Trial
Principal Investigator ·
Awarded by Pfizer, Inc. ·
2025 - 2027
Phase 3, multicenter, randomized, double-blind, group sequential, placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children
Clinical Trial
Principal Investigator ·
Awarded by Pfizer, Inc. ·
2025 - 2027
A Multicenter, Open-Label Study Evaluating the Long-Term Safety, and Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years
Clinical Trial
Principal Investigator ·
Awarded by Teva Branded Pharmaceutical Products R&D, Inc ·
2022 - 2027
A Phase 2B, Multicenter, 30-week, Prospective, Cross-over, Double-blind, Randomized, Placebo-controlled Study Followed by a 52-Week Open-label Extension Study to Evaluate the Efficacy and Safety of Basimglurant Adjunctive to Ongoing Anticonvulsive
Clinical Trial
Principal Investigator ·
Awarded by Noema Pharma ·
2022 - 2025
A Multicenter, Randomized, DoubleBlind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine in Pedia
Clinical Trial
Principal Investigator ·
Awarded by Teva Branded Pharmaceutical Products R&D, Inc ·
2022 - 2025
New daily persistent headache: Biomarker Study in Children and Adolescents
Research
Principal Investigator ·
Awarded by International Headache Society ·
2023 - 2025
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing the Efficacy, Safety, and Tolerability of Subcutaneous Administration of Fremanezumab Versus Placebo for the Preventative Treatment of Episodic Migraine in Pe
Clinical Trial
Principal Investigator ·
Awarded by Teva Branded Pharmaceutical Products R&D, Inc ·
2022 - 2025
Preventing Epilepsy Using Vigabatrin in Infants With Tuberous Sclerosis Complex (PREVeNT Trial)
Research
Principal Investigator ·
Awarded by University of Alabama at Birmingham ·
2018 - 2021
